國家衛生研究院 NHRI:Item 3990099045/13558
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 853419      在线人数 : 901
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/13558


    题名: A novel recombinant Fc gamma receptor-targeted survivin combines with chemotherapy for efficient cancer treatment
    其它题名: A novel recombinant Fcγ receptor-targeted survivin combines with chemotherapy for efficient cancer treatment
    作者: Wu, CC;Chiang, CY;Liu, SJ;Chen, HW
    贡献者: National Institute of Infectious Diseases and Vaccinology
    摘要: Formyl peptide receptor-like 1 inhibitor (FLIPr), an Fc gamma receptor (Fc gamma R) antagonist, can be used as a carrier to guide antigen-FLIPr fusion protein to Fc gamma R then enhances antigen-specific immune responses. Survivin, a tumor-associated antigen, is over-expressed in various types of human cancer. In this study, we demonstrate that recombinant survivin-FLIPr fusion protein (rSur-FLIPr) binds to Fc gamma Rs, and efficient uptake by dendritic cells in vivo. In addition, rSur-FLIPr alone stimulates survivin-specific immune responses, which effectively suppresses the tumor growth. The antitumor immunities are through TAP-mediated and CD8-dependent pathways. Furthermore, preexisting anti-FLIPr antibody does not abolish antitumor responses induced by rSur-FLIPr immunization. These results suggest that FLIPr is an effective antigen delivery vector and can be repeatedly used. Combination of chemotherapy with rSur-FLIPr treatment reveals a great benefit to tumor-bearing mice. Altogether, these findings suggest that rSur-FLIPr is a potential candidate for efficient cancer therapy.
    日期: 2021-07-12
    關聯: Biomedicines. 2021 Jul 12;9(7):Article number 806.
    Link to: http://dx.doi.org/10.3390/biomedicines9070806
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=2227-9059&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000676540900001
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85111008738
    显示于类别:[陳信偉] 期刊論文
    [劉士任] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    ISI000676540900001.pdf8768KbAdobe PDF230检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈